The sevoflurane output from the Oxford Miniature Vaporizer (OMV) was measured in a series of bench tests in a drawover system. Using a range of settings on two OMVs in series, output ranged from 0.5 to 5.9% with a 600 ml tidal volume at a rate of 12 breaths/min produced by a Penlon Multivent. The OMVs' output was steady over 40 minutes. In tests with tidal volumes ranging from 300 ml to 1200 ml, the OMVs' output was lower at higher minute volumes. When continuous flow of carrier gas at 7.2 l/min was used, the output was lower than at the equivalent intermittent flow rate. Using two OMVs with a drawover system appears to be a feasible technique for the induction and maintenance of sevoflurane anaesthesia. Clinical tests of sevoflurane drawover anaesthesia are now required so that the advantages of sevoflurane can gain wider application in field and military anaesthesia.
Drawover anaesthesia systems are simpler and cheaper than continuous flow systems and can function in the absence of compressed gases 1 . Sevoflurane has not been applied to drawover anaesthesia, mainly due to cost. Sevoflurane's properties, relatively fast induction of and recovery from anaesthesia and low cardiac and respiratory irritability, may be advantageous for field and military anaesthesia. Hence we measured the sevoflurane output from the Oxford Miniature Vaporizer 50 (OMV) to assess the feasibility of sevoflurane drawover anaesthesia.
METHOD
Two new OMVs in series, the Penlon Manley Multivent ventilator, Ambu E non-rebreathing valve and Ohmeda Lung Simulator were connected as shown in Figure 1 . The gases were scavenged with the operating room exhaust system. We used the electronically controlled and gas driven Multivent to produce different ventilation patterns. The compliance of the lung simulator was set at 50 ml/cmH 2 O and the resistance at 5 cmH 2 O/l/sec. Tidal and minute volumes were measured with a Wright respirometer distal to the Ambu E valve.
The OMV is a low resistance vaporizer designed primarily for use in drawover anaesthesia. It has a glycol compartment for temperature stabilization. It can be used with a variety of volatile anaesthetic agents, in both drawover and plenum modes 2 . We used the imprinted (non-agent specific) scale of 0 (Off) to 80 (Full) on the top of the OMVs. The OMVs were refilled to the 50 ml mark with sevoflurane before the start of each measurement.
The temperature of the operating room was maintained at 20 to 22°C. We did not warm or control the temperature of the vaporizers. We waited an hour between measurements to enable the temperature of the OMVs to equilibrate with room temperature.
Sevoflurane output was measured with a Marquette RAMS 250 portable mass spectrometer every minute for 10 minutes at each of the settings used in all tests, except test 5 where the output was measured for 40 minutes. Gas was sampled from the breathing tube connecting the Multivent to the Ambu E valve and then returned to the system. All measurements were carried out four times, with the mean noted in the results.
Test 1
Two OMVs were used at a Multivent ventilator rate of 12 breaths/min and "tidal volume" of 600 ml (minute volume 7.2 l/min). Firstly, one OMV was used at settings of 20, 40, 60 and 80. Then two OMVs were used in series, with the first OMV set at 80 and the second OMV at 20, 40, 60 and 80.
Test 2
Multivent tidal volumes of 300, 600, 900 and 1200 ml were used at a ventilator rate of 12 breaths/min. The output was also measured with a tidal volume of 300 ml and rate of 24 breaths/min. Each of these ventilation "patterns" was tested, firstly with a single OMV set at 80, and then with two OMVs, both set at 80.
Test 3
The output of the OMVs was measured using continuous flow of 7.2 l/min and 12 l/min of air from a Drager Narkomed anaesthetic machine. The flow was measured with the Wright respirometer. The Ambu E valve, lung simulator and Multivent were removed. For each continuous flow setting, the output was measured firstly with a single OMV at 80, and then with two OMVs, both set at 80.
Test 4
The output of the OMVs was measured during continuous flow from a Farman entrainer ( Figure 2 ). This device uses pressurized oxygen to entrain air and convert a drawover system into a continuous flow system. It is designed to deliver a total flow of 11.8 l/min when the mercury sphygmomanometer that is attached to the sidearm reads 100 mmHg. The oxygen flow was set accordingly to give a reading of 100 mmHg and a total gas flow of 11.8 l/min produced by oxygen and entrained air. Measurements were taken firstly with a single OMV set at 80, then with two OMVs in series both set at 80.
Test 5
This was carried out after the results of Test 1 were known. Based on Test 1, output at the 80 setting of the OMV filled with 50 ml sevoflurane was expected to last approximately 40 minutes. The output of one OMV set at 80 was measured for 40 minutes at a ventilator rate of 12 breaths/min and "tidal volume" of 600 ml. Then two OMVs in series were used, both set at 80. The OMVs were not refilled during the tests.
RESULTS
The results of Test 1 are in Figure 3 . There were small initial surges at all settings but these settled within five "breaths" in all measurements. The sevoflurane output at all settings stabilized within one minute and there was then a very gradual fall in the output over 10 minutes. The steady output with one OMV set at 80 (full) was 2.9% and that with two OMVs in series fully on was 5.9%. The results of Test 2 are shown in Table 1 . The output was highest at the lowest minute volume and fell with increasing minute volumes. The output at 5 and 10 minutes was similar when different tidal volumes and rates were used but with the same minute volume (300 ml at 24 breaths/min and 600 ml at 12 breaths/min).
The results of Test 3 are shown in Table 2 . The sevoflurane output with one OMV and two OMVs set at 80 (2.3% and 3.8% respectively) was lower when using 7.2 l/min continuous flow from an anaesthetic machine when compared to that with 7.2 l/min of intermittent Multivent "drawover" flow (2.9% and 5.8%). When using continuous flow of 12 l/min, the output with one and two OMVs set at 80 (1.5% and 3.0% respectively) was lower than that with a higher intermittent flow (1200 ml at 12 breaths/min in Test 2) of 14.4 l/min (2.0% and 4.2%).
The results of Test 4 are also in Table 2 . The steady output with one and two OMVs using 11.8 l/min continuous flow from the Farman entrainer (1.5% and 3.0%) was also significantly lower than when a higher intermittent flow of 14.4 l/min was used. The results of Test 5 are shown in Figure 4 . The output of the OMVs appeared to be steady over a period of 40 minutes even when the OMVs were nearly empty.
DISCUSSION
With two OMVs able to maintain an output of 6% for 10 minutes, induction of anaesthesia with sevoflurane in this drawover system appears feasible. A single OMV was capable of sustaining a sevoflurane output of over 2.5% over 40 minutes and the maintenance of anaesthesia also appears feasible. Using two OMVs, the range of sevoflurane output appears adequate for clinical use. In clinical practice, sevoflurane requirements can be reduced by premedication and opioid administration.
Previous tests of the OMV with halothane at paediatric tidal volumes of 50, 100 and 150 ml found that tidal volume had minimal effect on halothane output 3 . However with a larger magnitude of tidal volume differences, we found the sevoflurane output lower with large tidal volumes of 900 ml and 1200 ml, and higher with a tidal volume of 300 ml compared to that with a 600 ml tidal volume, all at the same ventilator rate. This suggests that higher settings will be required when ventilating at larger tidal volumes to achieve the same depth of anaesthesia.
While the versatility of OMV design enables it to be used in a variety of modes, the sevoflurane vaporizing ability of OMV appears to be better with the intermittent flow of drawover systems (its primary intended role) rather than with the continuous flow of plenum systems. We used the Farman entrainer at its calibrated flow of 11.8 l/min, but much lower flows will be used in clinical practice. Clinical study at lower continuous flows will help in assessing the feasibility of this mode. The OMV's halothane output has been shown to fall at continuous flow rates <4 l/min or >10 l/min 2 . This sensitivity to type of flow may be more pronounced when using higher concentrations of a less potent agent such as sevoflurane 4 .
As monitoring of anaesthetic concentrations may not be available in developing countries and in field situations, the ability of drawover vaporizers to maintain accurate and steady output is important. The sevoflurane output of the OMVs appeared steady over a 40 minute period even when nearly empty. One millilitre of liquid sevoflurane will be expected to produce 182 ml of vapor at 20°C 5 . We would expect an OMV filled to 50 ml to maintain an output of 3% for 42 min at a minute ventilation of 7.2 l/min. Refilling will be required for longer anaesthetics.
As the maximum output of a single OMV set fully on did not exceed 4.1% at the ventilation patterns used, it is unlikely that excessively deep anaesthesia will be produced with a single OMV during the "maintenance" phase of anaesthesia. This and the lower potency of sevoflurane may make sevoflurane drawover anaesthesia safer compared to halothane or isoflurane. It may be possible to use the OMV enflurane scale as the boiling points and saturated vapor pressures at 20°C of enflurane (56.5°C and 172 mmHg) and sevoflurane (58.5°C and 160 mmHg) are similar. A sevoflurane scale for the OMV is currently not available.
We did not attempt to maintain the temperature of the OMVs, as we wanted to measure the output under "normal" operating room conditions. Water baths have been used in a previous study to control the temperature to ±5°C 3 . They may even be useful for increasing the output of the vaporizers, but with the risk of excessive concentrations.
The OMV can be used in drawover spontaneous ventilation and drawover and "pushover" modes for intermittent positive pressure ventilation. We have not tested whether the output is different with sevoflurane and with the OMVs downstream of the ventilator (pushover mode). However, previous work with halothane has shown that the OMV works equally well in drawover or "pushover" mode 2, 4 . The positive pressure produced during controlled ventilation did not affect the OMV 4 . Further study is needed to measure the sevoflurane output during patients' spontaneous ventilation, as it is not possible to "completely simulate" human ventilation with the Multivent.
In conclusion, the sevoflurane output in bench tests of two OMVs in series appears to be adequate for both the induction and maintenance of sevoflurane drawover anaesthesia. Clinical study assessing sevoflurane drawover anaesthesia in patients is now required. This may enable the advantages of sevoflurane anaesthesia to gain wider application in field anaesthesia and in developing countries, particularly if the cost of sevoflurane falls in the future.
